Isolation of Compounds Including Two New Compounds from Asiasarum Root and Their Anti-glycation Activity.

IF 1.5 4区医学 Q4 CHEMISTRY, MEDICINAL

Chemical & pharmaceutical bulletin Pub Date : 2025-01-01 DOI:10.1248/cpb.c25-00034

Aiko Sano, Ryuichiro Suzuki

{"title":"Isolation of Compounds Including Two New Compounds from Asiasarum Root and Their Anti-glycation Activity.","authors":"Aiko Sano, Ryuichiro Suzuki","doi":"10.1248/cpb.c25-00034","DOIUrl":null,"url":null,"abstract":"<p><p>Two new glycosides, named 3-methoxy-5-methylphenol-6-O-β-glucopyranosyl-(1→6)-β-glucopyranoside (compound 1) and 1-O-feruloyl-α-arabinofuranosyl-(1→6)-β-glucopyranoside (compound 2), were isolated from Asiasarum root, together with eight known compounds. Asiasarum root (crude drug name in Latin: ASIASARI RADIX) is well known for its anti-inflammation and antitussive properties and is commonly found in Kampo formula in Japan. The structures of new compounds 1 and 2 were characterized using one- and two-dimensional (1D and 2D) NMR spectroscopy and MS. In addition, the anti-glycation activity of the isolates was evaluated. Glycation is particularly advanced in patients with diabetes and is suspected to be associated with diabetic complications such as nephropathy, osteoporosis, and Alzheimer's disease. The inhibition of this reaction is thought to be linked to the prevention and treatment of these diseases. Compounds 2 (79.4%), 4 (82.4%), 5 (79.8%), 6 (86.5%), 7 (90.1%), 9 (61.4%), and 10 (82.2%) showed activities comparable to that of aminoguanidine (45.3%) used as a positive control.</p>","PeriodicalId":9773,"journal":{"name":"Chemical & pharmaceutical bulletin","volume":"73 6","pages":"515-519"},"PeriodicalIF":1.5000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chemical & pharmaceutical bulletin","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1248/cpb.c25-00034","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Two new glycosides, named 3-methoxy-5-methylphenol-6-O-β-glucopyranosyl-(1→6)-β-glucopyranoside (compound 1) and 1-O-feruloyl-α-arabinofuranosyl-(1→6)-β-glucopyranoside (compound 2), were isolated from Asiasarum root, together with eight known compounds. Asiasarum root (crude drug name in Latin: ASIASARI RADIX) is well known for its anti-inflammation and antitussive properties and is commonly found in Kampo formula in Japan. The structures of new compounds 1 and 2 were characterized using one- and two-dimensional (1D and 2D) NMR spectroscopy and MS. In addition, the anti-glycation activity of the isolates was evaluated. Glycation is particularly advanced in patients with diabetes and is suspected to be associated with diabetic complications such as nephropathy, osteoporosis, and Alzheimer's disease. The inhibition of this reaction is thought to be linked to the prevention and treatment of these diseases. Compounds 2 (79.4%), 4 (82.4%), 5 (79.8%), 6 (86.5%), 7 (90.1%), 9 (61.4%), and 10 (82.2%) showed activities comparable to that of aminoguanidine (45.3%) used as a positive control.

查看原文本刊更多论文

亚洲细辛根中两种新化合物的分离及其抗糖化活性研究。

从Asiasarum根中分离到了两个新的苷类化合物，分别命名为3-甲氧基-5-甲基苯酚-6- o -β-glucopyranosyl-(1→6)-β-glucopyranoside（化合物1）和1- o -阿魏酰-α-arabinofuranosyl-(1→6)-β-glucopyranoside（化合物2）。亚洲细辛根（拉丁原料药名：ASIASARI RADIX）以其抗炎和止咳的特性而闻名，在日本的汉布配方中很常见。利用一维和二维（1D和2D）核磁共振波谱和质谱对新化合物1和2的结构进行了表征，并对其抗糖基化活性进行了评价。糖化在糖尿病患者中尤其晚期，被怀疑与糖尿病并发症如肾病、骨质疏松症和阿尔茨海默病有关。抑制这种反应被认为与预防和治疗这些疾病有关。化合物2（79.4%）、4（82.4%）、5（79.8%）、6（86.5%）、7（90.1%）、9（61.4%）和10（82.2%）的活性与阳性对照氨基胍（45.3%）相当。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Chemical & pharmaceutical bulletin 医学-化学综合

CiteScore

3.20

自引率

5.90%

发文量

132

审稿时长

1.7 months

期刊介绍： The CPB covers various chemical topics in the pharmaceutical and health sciences fields dealing with biologically active compounds, natural products, and medicines, while BPB deals with a wide range of biological topics in the pharmaceutical and health sciences fields including scientific research from basic to clinical studies. For details of their respective scopes, please refer to the submission topic categories below. Topics: Organic chemistry In silico science Inorganic chemistry Pharmacognosy Health statistics Forensic science Biochemistry Pharmacology Pharmaceutical care and science Medicinal chemistry Analytical chemistry Physical pharmacy Natural product chemistry Toxicology Environmental science Molecular and cellular biology Biopharmacy and pharmacokinetics Pharmaceutical education Chemical biology Physical chemistry Pharmaceutical engineering Epidemiology Hygiene Regulatory science Immunology and microbiology Clinical pharmacy Miscellaneous.